This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • PROfound
      • VISION Trial
    • mHSPC
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • PSMA PET Imaging
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
  • Trials in Progress
    • Trials in Progress
      • ARAMON Trial
      • ARASEC Trial
      • ARASTEP Trial
      • ECLIPSE Trial
      • Oral EPI-7386
      • SPLASH Trial
    • Right Side
      • PCCTC
        • DORA
        • IRONMAN
        • PROMISE
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Health Policy
          • Health Policy
            Ruchika Talwar, MD
        • Bladder Cancer
          • Bladder Cancer
            Ashish Kamat, MD
          • Advanced Bladder Cancer
            Petros Grivas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
          • Kidney Cancer Today
            Sumanta (Monty) Kumar Pal, MD
            Jaime Landman, MD
      • Prostate Cancer
        • Advanced Prostate Cancer
          Alicia Morgans, MD, MPH
        • CRPC with Bone Metastases
          Rana R. McKay, MD
        • Imaging Center
          Phillip Koo, MD
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • mHSPC
          Alicia Morgans, MD, MPH
        • nmCRPC
          Alicia Morgans, MD, MPH
        • PSMA-Targeted Therapy
      • Disparities: Social Determinants of Health
        • Disparities: Social Determinants of Health
          Samuel L. Washington III, MD, MAS
      • Translational Prostate Cancer
        • Translational Science in Prostate Cancer
          Andrea Miyahira, Ph.D
        • Women in Science
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • TESTICULAR, PENILE & RARE GU MALIGNANCIES
        • Testicular, Penile, and Rare GU Malignancies
    • Pelvic Health & Reconstruction
      • Bladder Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Pelvic Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
        Stephen R. Kraus, MD
      • Urologic Catheters (Includes CAUTI)
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Suprapubic Catheter
        Diane K. Newman, DNP FAAN BCB-PMD
  • Videos
    • Exclusives
      • Conferences
      • Exclusive Collaborations
      • Independent Education
      • Covid-19
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Pelvic Health & Reconstruction
      • Endourology
      • Testicular Cancer
      • Health Policy in Urological Diseases
      • Disparities: Social Determinants of Health
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • ASCO 2023
      • AUA 2023
      • ASCO GU 2023
      • EAU 2023
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Recent Abstracts
  3. Urologic Oncology
  4. Prostate Cancer

Conferences

Recent Abstracts
ASCO 2023: Long-Term Outcomes of Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial June 4, 2023
ASCO 2023: Primary Analysis of STARTAR: A Phase 2 Salvage Trial of ADT and Apalutamide with Radiation Therapy Followed by Docetaxel in Men with PSA Recurrent Prostate Cancer After Radical Prostatectomy June 4, 2023
ASCO 2023: ARAMON: A Phase 2, Randomized, Open-Label Study Comparing the Effects of Darolutamide Versus Enzalutamide Monotherapy on Serum Testosterone Levels in Patients with Hormone-Naive Prostate Cancer June 4, 2023
ASCO 2023: Tumor Factors and the Variation in Non-Muscle Invasive Bladder Cancer Recurrence After Transurethral Resection Surgery Between Sites: Results from the RESECT Study June 4, 2023
ASCO 2023: Discussant: Looking for Prostate Cancer: Will Novel Imaging Light the Way? June 4, 2023
ASCO 2023: Pre-Surgical 68Ga-PSMA-11 PET for Biochemical Recurrence Risk Assessment: A Surrogate of Pelvic Lymph Node Dissection? Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial June 4, 2023
ASCO 2023: PANTHER: A Prospective Trial of Apalutamide and Abiraterone Acetate plus Prednisone in Black and White Men with mCRPC June 4, 2023
ASCO 2023: Do Bone Scans Over-Stage Disease Compared to PSMA PET? an International Multicenter Retrospective Study with Blinded Independent Readers June 4, 2023
ASCO 2023: Patient Reported Quality of Life and Survival Outcomes: Analysis of ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED) in Prostate Cancer June 4, 2023
ASCO 2023: A Study of Prospective Monitoring of Patients with Recurrent Prostate Cancer Using Serial 18F-DCFPyL PSMA Imaging June 4, 2023
ASCO 2023: Enfortumab Vedotin with or Without Pembrolizumab in Patients Who Are Cisplatin-Ineligible with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer: Additional 3-Month Follow-up on Cohort K Data June 4, 2023
ASCO 2023: Health-Related Quality of Life and Pain Outcomes for Patients with mCRPC Who Received Abiraterone and Olaparib Vs Abi and Placebo in the Phase III PROpel Trial June 4, 2023
ASCO 2023: Patient-Reported Outcomes Among Men Receiving Talazoparib + Enzalutamide vs Placebo + ENZA as First-Line Treatment for mCRPC: Results from a Phase 3 Study (TALAPRO-2) June 4, 2023
ASCO 2023: Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography Disease Extent and Overall Survival in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer: An International Multicenter Retrospective Study June 3, 2023
ASCO 2023: PSMA PET Guided Salvage Radiotherapy Among Patients with Prostate Cancer in the Post-Prostatectomy Setting: A Single Center Post-Hoc Analysis June 3, 2023
ASCO 2023: The Role of Volume of Disease for Treatment Selection in Patients with mCSPC: A Living Meta-Analysis June 3, 2023
ASCO 2023: APPROACH Trial: Multimodal Approach in Patients with mHSPC: A Pragmatic, Randomized, Phase 3 Trial of Androgen-Deprivation Therapy plus Apalutamide Versus ADT plus Apalutamide and Local Treatment—Meet-URO 29 Study June 3, 2023
ASCO 2023: Building a Predictive Model for Outcomes with 177Lu-PSMA-617 in Patients with mCRPC Using VISION Data: Preliminary Results June 3, 2023
ASCO 2023: ADT and Risk of Dementia in Patients with Prostate Cancer: Clinical Outcomes from Real-World Data June 3, 2023
ASCO 2023: Tumor Dosimetry of 177Lu-PSMA-617 for the Treatment of mCRPC: Results from the VISION Trial Sub-Study June 3, 2023
Page 5 of 522
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2023 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free